Yongkai Lu

Dr. Yongkai Lu

the First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shaanxi, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YLYongkai Lu
Yongkai Lu
DYDi Yang
Di Yang
XZXiaowei Zhang
Xiaowei Zhang
YTYonggang Teng
Yonggang Teng
WYWei Yuan
Wei Yuan
YLYi Li
Yi Li
Objectives: Modern breast cancer techniques, such as the deep inspiration breath-hold (DIBH) technique has been applied for left-sided breast cancer. Whether the DIBH regimen is the optimal solution for left-sided breast cancer remains unclear. This meta-analysis aims to elucidate the differences of DIBH and free-breathing (FB) for patients receiving radiotherapy for left-sided breast cancer and provide a practical reference for clinical practice.Methods: Relevant research available on PubMed, Embase, Cochrane Library, and the Web of Science published before November 30, 2021 was independently and systematically examined by two investigators. Data were extracted from eligible studies for assessing their qualities and calculating the standardized mean difference (SMD) and 95% confidence intervals (CIs) using Review Manager software 5.4 (RevMan 5.4).Results: Forty-one studies with a total of 3599 left-sided breast cancer patients were included in the meta-analysis. Compared with FB, DIBH reduced heart dose (Dmean, Dmax, V30, V10, V5), left anterior descending branch (LAD) dose (Dmean, Dmax), ipsilateral lung dose (Dmean, V20, V10, V5), and heart volume significantly. Lung volume increased greatly, and a statistically significant difference. For contralateral breast mean dose, DIBH has no obvious advantage over FB. The funnel plot suggested this study has no significant publication bias.Conclusions: Although DIBH has no obvious advantage over FB in contralateral breast mean dose, it can significantly reduce heart dose, LAD dose, ipsilateral lung dose, and heart volume. Conversely, it can remarkably increase the ipsilateral lung volume. This study suggests that soon DIBH could be more widely utilized in clinical practice because of its excellent dosimetric performance.

6 February 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YLYongkai Lu
Yongkai Lu
BHBeina Hui
Beina Hui
DYDi Yang
Di Yang
YLYi Li
Yi Li
BLBinglin Li
Binglin Li
DZDongli Zhao
Dongli Zhao
Objectives: In this meta-analysis, we conducted a comparative analysis of the safety and efficacy of hypofractionated and conventional fractionated radiotherapy in individuals who had undergone surgery for breast cancer. Methods: This study involved a systematic and independent review of relevant research articles published in reputable databases such as PubMed, Embase, Cochrane Library, and Web of Science. Two investigators conducted the review, which included studies published up to January 3, 2023. The quality of the eligible studies was evaluated and data were extracted using Review Manager software 5.4 (RevMan 5.4) to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results: The analysis comprised 35 studies and encompassed a collective sample of 18,246 individuals diagnosed with breast cancer. We did not find a statistically significant disparity in efficacy between conventional fractionated (CF) radiotherapy and hypofractionated (HF) radiotherapy regarding local recurrence (LR; OR = 0.91, 95% CI: 0.76–1.09, P = 0.30), disease-free survival (DFS; OR = 1.20, 95% CI: 1.01–1.42, P = 0.03), and overall survival (OS; OR = 1.08, 95% CI: 0.93–1.26, P = 0.28). Concerning safety, there was no significant difference between the HF and CF regimens in terms of breast pain, breast atrophy, lymphedema, pneumonia, pulmonary fibrosis, telangiectasia, and cardiotoxicity. However, the HF regimen resulted in lower skin toxicity (OR = 0.43, 95% CI: 0.33—0.55, P < 0.01) and improved patient fatigue outcomes (OR = 0.73, 95% CI: 0.60 – 0.88, P < 0.01). Conclusions: Although there is no substantial difference in LR, DFS, OS, or many other side effects between the HF and CF regimens, the HF regimen reduces skin toxicity and relieves patient fatigue. If these two issues need to be addressed in clinical situations, the HF regimen may be a superior alternative to conventional radiotherapy in postoperative breast cancer patients.

16 August 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYongkai Lu
Yongkai Lu
YMYanfang Ma
Yanfang Ma
DYDi Yang
Di Yang
YLYi Li
Yi Li
WYWei Yuan
Wei Yuan
DZDongli Zhao
Dongli Zhao
There is uncertainty regarding the benefits and drawbacks of various radiation protocols for the treatment of left-sided breast cancer. To address this issue, we conducted a Bayesian network analysis. First, we searched several electronic databases for eligible literature. Next, we pooled the data from twelve studies concerning three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), and volumetric modulated arc therapy (VMAT), combined with either deep inspiratory breath-holding (DIBH) or free-breathing (FB) modalities. The integrated cardiac and pulmonary dosimetric indexes for all included treatments were compared using Bayesian networks. A direct meta-analysis indicated that for the two methods of 3D-CRT and IMRT, DIBH technology was more effective than FB in reducing the radiation dose to the heart and lungs. Additionally, according to the network results, DIBH was superior to FB in all six treatment options, regardless of whether the plan was 3D-CRT, IMRT, or VMAT. Besides, the combined data indicated that the FB-3D-CRT regimen had the weakest dosimetric advantage of all the treatments. Excluding FB-3D-CRT, each of the other five treatments had its own specific benefits. This is the first Bayesian study of several radiotherapy regimens for breast cancer patients on the left side, and the findings can be used to select appropriate radiotherapy programs for breast cancer patients.

2 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YLYi Li
Yi Li
WWWenjing Wu
Wenjing Wu
YSYuchen Sun
Yuchen Sun
DYDequan Yu
Dequan Yu
YZYuemei Zhang
Yuemei Zhang
YLYongkai Lu
Yongkai Lu
Purpose: Our purpose was to investigate the influence of atlas library size and CT cross-slice number on the accuracy and efficiency of the atlas-based auto-segmentation (ABAS) method for the automatic contouring of clinical treatment volume (CTV) and organs at risk (OARs) during cervical cancer radiotherapy.Methods: Of 140 cervical cancer patients, contours from 20, 40, 60, 80, 100, and 120 patients were selected incrementally to create six atlas library groups in ABAS. Another 20 tested patients were automatically contoured with the ABAS method and manually contoured by the same professional oncologist. Contours included CTV, bladder, rectum, femoral head-L, femoral head-R, and spinal cord. The CT cross-slice numbers of the 20 tested patients included 61, 65, 72, 75, 81, and 84. The index of dice similarity coefficients (DSCs) and Hausdorff distance (HD) were used to assess the consistency between ABAS automatic contouring and manual contouring. The randomized block analysis of variance and paired t-test were used for statistical analysis.Results: The mean DSC values of “CTV, bladder, femoral head, and spinal cord” were all larger than 0.8. The femoral head and spinal cord showed a high degree of agreement between ABAS automatic contouring and manual contouring, with a mean DC >0.80 and HD <1 cm in all atlas library groups. A post-hoc least significant difference comparison indicated that no significant difference had been found between different atlas library sizes with DSC and HD values. For ABAS efficiency, the atlas library size had no effect on the time of ABAS automatic contouring. The time of automatic contouring increased slightly with the increase in CT cross-slice numbers, which were 99.9, 106.8, 114.0, 120.6, 127.9, and 134.8 s with CT cross-slices of 61, 65, 72, 75, 81, and 84, respectively.Conclusion: A total of 20 atlas library sizes and a minimum CT cross-slice number including CTV and OARs are enough for ensuring the accuracy and efficiency of ABAS automatic contouring during cervical cancer radiotherapy.

7 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
WWWenjing Wu
Wenjing Wu
RHRuixin He
Ruixin He
YLYongkai Lu
Yongkai Lu
YZYuemei Zhang
Yuemei Zhang
XZXiaozhi Zhang
Xiaozhi Zhang
Inter-fractional tumor variance would lead to insufficient dosage or overdose in tumor region during lung cancer radiotherapy. However, previous works have not considered influence of inter-fractional tumor amplitude variance at treatment position due to lack of effective evaluation method during radiotherapy, especially for lung tumor within the lower lobe. Our objective was to investigate inter-fractional tumor baseline shift and amplitude variance due to respiratory motion with 4DCBCT simulation and guidance during stereotactic ablative body radiotherapy (SABR) for lung tumor. Subject included 19 patients with lung tumor within the lower lobe. 4DCBCT-simulated images at treatment position were acquired sequentially to determine internal tumor volume (ITV) and reference tumor motion at simulation process. Compared with reference tumor motion, 95 4DCBCT-guided images were acquired during each treatment to evaluate inter-fractional tumor baseline shift and amplitude variance, which were − 0.0 ± 1.3 mm and − 0.2 ± 1.4 mm in left–right(LR) direction, 0.9 ± 2.3 mm and 0.4 ± 2.9 mm in superior-inferior (SI) direction, 0.1 ± 1.5 mm and − 0.4 ± 2.0 mm in anterior–posterior (AP) direction. ITV margin were 3.5 mm, 7.5 mm and 5.3 mm in LR, SI and AP directions with van Herk’s (Int J Radiat Oncol Biol Phys 52(5):1407–1422, 2002) formula. 4DCBCT simulation and guidance is a reliable method to evaluate inter-fractional tumor variance during SABR for lung tumor within the lower lobe. ITV margin of 3.5 mm, 7.5 mm and 5.3 mm in LR, SI and AP directions would ensure greater tumor coverage during SABR for lung tumor within the lower lobe.

22 October 2021 in Medicine
Verified
Journal Article
Open access
RCRuijuan Chen
Ruijuan Chen
YLYongkai Lu
Yongkai Lu
YZYuemei Zhang
Yuemei Zhang
RHRuixin He
Ruixin He
FTFengwen Tang
Fengwen Tang
XZXiaowei Zhang
Xiaowei Zhang
Purpose: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains unclear. This meta-analysis aims to elucidate and compare the efficacy and toxicity of TPF+CCRT versus CCRT alone for LA-NPC. Methods: Two investigators independently and systematically searched relevant studies available on PubMed, Embase, Cochrane Library, and Web of Science published before January 7, 2021. Data were extracted from eligible studies for assessing their qualities, and calculating pooled hazard ratios (HR), odds ratio (OR) and 95% confidence intervals (CI) using Review Manager software 5.3 (RevMan 5.3). Results: Five studies involving 759 LA-NPC patients were analyzed in the meta-analysis. Compared to CCRT alone, TPF-based IC plus CCRT significantly improved overall survival (OS) (HR = 0.53, 95% CI: 0.35–0.81, P = .003), progression-free survival (PFS) (HR = 0.63, 95% CI: 0.46–0.86, P = .004), distant metastasis-free survival (DMFS) (HR = 0.58, 95% CI: 0.39–0.86, P = .008), and locoregional failure-free survival (LRFFS) (HR 0.62, 95% CI: 0.43–0.90, P = .01). In addition, TPF-based IC plus CCRT mainly increased risks of grade 3/4 acute hematological toxicity and non-hematological toxicities like leukopenia (OR = 1.84, 95% CI: 0.42–8.03, P = .42), neutropenia (OR = 1.78, 95% CI: 0.23–13.82, P = .58), thrombocytopenia (OR = 1.76, 95% CI: 0.53–5.81, P = .35), febrile neutropenia (OR = 2.76, 95% CI: 0.07–101.89, P = .58), vomiting (OR = 18.94, 95% CI: 0.99–362.02, P = .05) and dry mouth (OR = 2.23, 95% CI: 0.22–22.57, P = .50), which were uncomplicated and manageable. Conclusions: TPF + CCRT is superb than CCRT alone for the management of LA-NPC. However, TPF+CCRT increases the incidences of grade 3/4 acute hematological toxicity and some non-hematological toxicities.